Originally published byEU-Startups
Cellply, a Bologna-based DeepTech startup developing analytical tools enabling a deep characterisation of cancer immunotherapies, cell therapies and cell-based biotherapeutics, has completed the largest portion of its latest funding round, securing €7.15 million to date. The investment was led by ENEA Tech e Biomedical, with additional participation from existing shareholders, including the SAFE conversion into […]
The post Bologna’s Cellply secures €7.15 million to develop tools for faster immunotherapy and cell therapy development appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Securing the Untrusted Agentic Development Layer
1d ago
Inside Legora’s hunt for legal tech acquisitions
12h ago
The talent profile Europe's top AI scaleups are chasing
12h ago
Linux kernel maintainers pitch emergency killswitch after CopyFail and Dirty Frag chaos
2d ago
A PhD pivot, a stint in VC and a rumoured Anthropic deal: why Europe is watching Walter Goodwin
1d ago